JP2024023347A5 - - Google Patents

Info

Publication number
JP2024023347A5
JP2024023347A5 JP2023196788A JP2023196788A JP2024023347A5 JP 2024023347 A5 JP2024023347 A5 JP 2024023347A5 JP 2023196788 A JP2023196788 A JP 2023196788A JP 2023196788 A JP2023196788 A JP 2023196788A JP 2024023347 A5 JP2024023347 A5 JP 2024023347A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
patient
infliximab
composition according
subcutaneous administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023196788A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024023347A (ja
Filing date
Publication date
Priority claimed from KR1020180017449A external-priority patent/KR20190024572A/ko
Application filed filed Critical
Publication of JP2024023347A publication Critical patent/JP2024023347A/ja
Publication of JP2024023347A5 publication Critical patent/JP2024023347A5/ja
Pending legal-status Critical Current

Links

JP2023196788A 2017-08-30 2023-11-20 ＴＮＦα関連疾患の治療方法 Pending JP2024023347A (ja)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
KR20170110426 2017-08-30
KR10-2017-0110426 2017-08-30
KR10-2017-0144521 2017-11-01
KR20170144521 2017-11-01
KR10-2018-0017449 2018-02-13
KR1020180017449A KR20190024572A (ko) 2017-08-30 2018-02-13 TNFα 관련 질환을 치료하기 위한 피하 투여 요법
PCT/KR2018/009998 WO2019045452A1 (ko) 2017-08-30 2018-08-29 TNFα 관련 질환을 치료하는 방법
JP2020512018A JP7838891B2 (ja) 2017-08-30 2018-08-29 ＴＮＦα関連疾患の治療方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020512018A Division JP7838891B2 (ja) 2017-08-30 2018-08-29 ＴＮＦα関連疾患の治療方法

Publications (2)

Publication Number Publication Date
JP2024023347A JP2024023347A (ja) 2024-02-21
JP2024023347A5 true JP2024023347A5 (enExample) 2026-05-11

Family

ID=65801706

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020512018A Active JP7838891B2 (ja) 2017-08-30 2018-08-29 ＴＮＦα関連疾患の治療方法
JP2023196788A Pending JP2024023347A (ja) 2017-08-30 2023-11-20 ＴＮＦα関連疾患の治療方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020512018A Active JP7838891B2 (ja) 2017-08-30 2018-08-29 ＴＮＦα関連疾患の治療方法

Country Status (27)

Country Link
US (2) US20210371510A1 (enExample)
EP (1) EP3677596A4 (enExample)
JP (2) JP7838891B2 (enExample)
KR (3) KR20190024572A (enExample)
CN (1) CN111094342A (enExample)
AR (1) AR135171A2 (enExample)
AU (2) AU2018326037B2 (enExample)
BR (1) BR112020003951A2 (enExample)
CL (1) CL2020000479A1 (enExample)
CO (1) CO2020002117A2 (enExample)
CR (1) CR20200095A (enExample)
CU (1) CU20200015A7 (enExample)
DO (1) DOP2020000049A (enExample)
EA (1) EA202090544A1 (enExample)
EC (1) ECSP20014569A (enExample)
GE (2) GEP20237521B (enExample)
IL (1) IL272977A (enExample)
JO (1) JOP20200046A1 (enExample)
MA (1) MA50046A (enExample)
MX (1) MX2020002278A (enExample)
PE (1) PE20200889A1 (enExample)
PH (1) PH12020550066A1 (enExample)
SG (1) SG11202001739YA (enExample)
TW (1) TWI887196B (enExample)
UA (1) UA130480C2 (enExample)
WO (1) WO2019045452A1 (enExample)
ZA (1) ZA202001927B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR118191A1 (es) * 2019-02-28 2021-09-22 Celltrion Inc MÉTODOS PARA EL TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON TNFa
WO2023014992A1 (en) * 2021-08-06 2023-02-09 AndorHealth, LLC Virtual care systems and methods
KR20260087771A (ko) * 2024-12-04 2026-06-12 (주)셀트리온 TNFα 관련 질환을 치료하는 방법

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4861335A (en) 1985-07-26 1989-08-29 Duoject Medical Systems Inc. Syringe
US5085642A (en) 1989-07-17 1992-02-04 Survival Technology, Inc. Conveniently carried frequent use autoinjector
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
DE69319753T2 (de) 1992-11-19 1999-04-15 Tebro S.A., Luxembourg Automatische injektionsvorrichtung für vorgefüllte spritzen
DE4438360C2 (de) 1994-10-27 1999-05-20 Schott Glas Vorfüllbare partikelarme, sterile Einmalspritze für die Injektion von Präparaten und Verfahren zu ihrer Herstellung
US20050249735A1 (en) * 2000-08-07 2005-11-10 Centocor, Inc. Methods of treating ankylosing spondylitis using anti-TNF antibodies and peptides of human tumor necrosis factor
CA2817619A1 (en) * 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US20030206898A1 (en) * 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
US20040131614A1 (en) * 2002-07-19 2004-07-08 Abbott Biotechnology Ltd. Treatment of pulmonary disorders using TNFalpha inhibitor
TWI439284B (zh) * 2004-04-09 2014-06-01 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
US20100278822A1 (en) * 2009-05-04 2010-11-04 Abbott Biotechnology, Ltd. Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
TWI603739B (zh) * 2010-11-11 2017-11-01 艾伯維生物技術有限責任公司 具有增進高濃度之抗－ＴＮＦα抗體之液體調配物
GB201112429D0 (en) * 2011-07-19 2011-08-31 Glaxo Group Ltd Antigen-binding proteins with increased FcRn binding
WO2013087914A1 (en) * 2011-12-16 2013-06-20 Synthon Biopharmaceuticals B.V. EXPRESSION OF SECRETORY IgA ANTIBODIES IN DUCKWEED
WO2014114651A1 (en) * 2013-01-24 2014-07-31 Glaxosmithkline Intellectual Property Development Limited Tnf-alpha antigen-binding proteins
EP3078675A1 (en) * 2015-04-10 2016-10-12 Ares Trading S.A. Induction dosing regimen for the treatment of tnf alpha mediated disorders
KR20170081814A (ko) 2016-01-05 2017-07-13 이경록 헤어 브러시
EP3411401A1 (en) * 2016-02-03 2018-12-12 Oncobiologics, Inc. Buffer formulations for enhanced antibody stability
UA122610C2 (uk) * 2016-06-30 2020-12-10 Селлтріон Інк. Стабільний рідкий фармацевтичний склад

Similar Documents

Publication Publication Date Title
JPH07504888A (ja) ＣＤｗ５２−多発性硬化症の治療のための特異抗体
JP2019514974A5 (enExample)
JP7794735B2 (ja) 切替え療法によるｒｍｓの治療
Gabay et al. Biological agents in monotherapy for the treatment of rheumatoid arthritis
JP2005506345A5 (enExample)
JP2019507775A5 (enExample)
JP2022523530A (ja) 化膿性汗腺炎の治療のための抗ＩＬ－α抗体
JPH0637395B2 (ja) ジペプタイド誘導体を含有する、筋萎縮性側索硬化症を治療するための薬剤
CN114375306A (zh) 奥法木单抗治疗患者中除多发性硬化症以外病症的管理
JP2024531314A5 (enExample)
JP2023526890A (ja) Ｃｏｖｉｄ－１９を包含するコロナウイルスの負の効果を処置および低減をするための抗ｃｄ６抗体組成物および方法
Mihăilă et al. Eltrombopag in chronic hepatitis C
AU2021382954B2 (en) Pharmaceutical composition, pharmaceutical combined formulation, and combined formulation kit for prevention or treatment of chronic hepatitis b, each comprising, as active ingredient, oral antiviral agent and therapeutic vaccine including lipopeptide and poly(i:c) adjuvant
JP2003525907A (ja) Ｈｉｖ免疫アジュバント治療
WO2018081090A1 (en) Compositions and methods for the treatment of hbv infection
EP3621628B1 (en) Method for treating multiple sclerosis using arsenic trioxide
US20260053790A1 (en) Treatments for conditions involving increased il-6 levels
CA3176673A1 (en) Pan-elr+ cxc chemokine antibodies for the treatment of respiratory disease
Schapiro Medications used in the treatment of multiple sclerosis
JP2022512721A (ja) 化膿性汗腺炎の治療のための汎ｅｌｒ＋ｃｘｃケモカイン抗体
WO2025209479A1 (en) Methods of treatment of immune thrombocytopenia using sovleplenib
US20260097063A1 (en) Anti-c5 antibody/c5 irna dosing regimens for treating c5-associated diseases
EP4029503B1 (en) Drug combinations of entecavir and a tlr7 agonist for use in the treatment of hbv
WO2025209478A1 (en) Methods of treatment warm autoimmune hemolytic anemia using sovleplenib
Reichert Adalimumab (humira®)